Drug intelligence / Profile preview

GRC 17356

Development stage: Preclinical
Lead developer: Glenmark Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GRC 17356 is an investigational drug developed by Glenmark Pharmaceuticals for the treatment of diabetic peripheral neuropathy (DPN)[4]. It is expected to enter the market as a novel therapy for DPN, addressing an unmet need due to limited efficacy and side effects associated with currently approved treatments. The specific mechanism of action, molecular target, and detailed pharmacological profile of GRC 17356 have not been disclosed in publicly available sources as of June 2025. However, it is listed among promising pipeline therapies anticipated to launch by 2030 for DPN[4].

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on GRC 17356.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRC 17356.

Explore the full profile